Summary: Sequential multiple assignment randomization trial (SMART) is a powerful design to study Dynamic Treatment Regimes (DTRs) and allows causal comparisons of DTRs.To handle practical challenges of SMART study, we propose a SMART with Enrichment (SMARTer) design, which can potentially improve the design efficiency, shorten the recruitment period, and reduce the trial duration to make SMART more practical with limited time and resource. Specifically, at each subsequent stage of a SMART, we enrich the study sample with new patients who have received previous stages' treatments in a naturalistic fashion without randomization, and only randomize them among the current stage treatment options. One extreme case of the SMARTer is to synthesize separate independent single-stage randomized trials with patients who have received previous stage treatments. We show data from SMARTer allows for unbiased estimation of DTRs as SMART does under certain assumptions. Furthermore, we show analytically that the efficiency gain of the new design over SMART can be significant especially when the dropout rate is high. Lastly, extensive simulation studies are performed to demonstrate performance of SMARTer design, and sample size estimation in a scenario informed by real data from a SMART study is presented.
Introduction
Dynamic Treatment Regimes (DTRs), also referred to as adaptive treatment regimes or tailored treatment regimens, are sequential treatment rules tailored at each stage by patients' time-varying characteristics and intermediate treatment responses Dawson and Lavori, 2004) . For example, an oncologist aiming to prolong survival for a cancer patient might use intermediate outcomes such as patient's tumor response to induction therapy to guide the use of second-line therapy. Sequential multiple assignment randomization trials (SMARTs) Dawson, 2000, 2004; Murphy, 2005) generalize conventional randomized clinical trials to make causal comparisons of such DTRs.
In SMARTs, patients are randomized to different treatments at each critical decision stage, where randomization probabilities may depend on patients' time-varying information up to that stage. These trials also provide rich information to infer optimal treatment regimes tailored to individual patients. Murphy (Murphy, 2005) provides inferences and sample size formula to compare two DTRs in SMARTs, Almirall et al. proposed to use SMART design as a pilot study for building effective DTRs, and Nahum-Shani et al. (Nahum-Shani et al., 2012) illustrated several important design issues and primary analyses for SMART studies.
were randomized to (JASP+EMT+SGD) or intensified (JASP+EMT+SGD) with equal probability. The second stage lasted 12 weeks and followed by a follow up stage of 12 weeks. In this study, the primary aim was to compare the first stage treatment options SGD (JASP+EMT+SGD) verses spoken words alone (JASP+EMT). Secondary aim was to compare the dynamic treatment regimes (DTRs), namely: 1. beginning with JASP+EMT+SGD and intensifying JASP+EMT+SGD for slow responders; 2 beginning with JASP+EMT and to increase the intensity for slow responders; 3. beginning with JASP+EMT and to switch JASP+EMT+SGD for slow responders.
Study dropout is a common phenomenon in randomized clinical trials (RCTs) regardless of investigator's best efforts to keep patients in the study. For example, meta analyses of study dropout rate for RCTs of antipsychotic drugs reported an average attrition rate of greater than 30% (Martin et al., 2006; Kemmler et al., 2005) . For multi-stage SMARTs, even higher dropout rate might be expected. Although smaller SMARTs maybe have lower drop out rate (e.g., 15% in Kasari et al., 2014) , attrition is still an issue not to be ignored in the planning stage. In the Clinical Antipsychotic Trials of Intervention and Effectiveness (CATIE) study (Schneider et al., 2003) , the attrition was high with 705 of 1460 patients (48%) staying for the entire 18 months. In a two-stage randomized trial on induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest (Joss et al., 1994) , only 118 of 266 patients (44%) entered the second stage randomization. Designing a SMART may thus require a larger sample size in the initial stage to ensure sufficient power for comparing DTRs in a multi-stage trial. In addition, it is time-consuming and challenging to manage and monitor a sequential multi-stage trial with a large sample size and long follow-up time.
The time and resource constraints may limit the ability of SMART studies to answer many important clinical questions regarding DTRs.
In this work, we propose an innovative design and a meta-analytic approach to enrich SMART sample and to synthesize single-stage trials without sacrificing the central feature of SMART to make causal conclusions. We show that the proposed SMART with Enrichment design (SMARTer) and its appropriate analysis method significantly boost the efficiency of SMART, address the attrition issue from the design and analysis perspective, improve practicability of SMART, and avoid pitfalls of incorrect inference on long term DTR effect when combining single-stage randomized trials. Specifically, the proposed methodology can potentially (1) extract information from patients dropping out from the first stage; (2) recruit and randomize additional patients to the second-stage treatments without requiring randomization of the first-stage treatments, and thus achieve the same or superior efficiency as if there were no dropouts, which reduces the sample size of the initial stage and the overall sample size; and (3) synthesize single-stage trials to integrate information to make causal inference on DTRs as is possible in a multi-stage SMART, while substantially shortening the trial time frame.
It is of interest to note that the proposed SMARTer design differs from an intuitive approach that pieces together results from separate randomized trials conducted at separate stages, as criticized in previous literature Collins et al., 2014) . For the latter, an investigator may determine the best first-line treatment based on a conventional randomized trial comparing several first-line treatments and then next, compare second-line treatments for a new group of subjects already treated by the "best" first-stage treatment.
Essentially, this intuitive approach compares available intervention options at each stage separately to infer the best DTR. It has several disadvantages : first, it does not capture the delayed effect when the long term effect begins to appear in latter stages; second, it fails to take into account the prescriptive effect of an early stage treatment which may not yield a larger intermediate outcome; third, single-stage trials tend to enroll more homogeneous patients to increase power for detection of treatment differences whereas SMART would not. In terms of design, SMARTer does not recommend enriching the sample with only the subjects who have received the "best" first-line treatment inferred from a single-stage trial. Instead, we recruit enrichment samples from subjects who have received any of the first-line treatments so that the enrich population includes patients with all possible combinations of both lines of treatments to properly account for delayed effect and prescriptive effect. The main focus of SMARTer design is to improve efficiency through enrichment samples who only receive randomization in the latter stages. In terms of the analysis, instead of inferring the best treatment from each single stage separately, SMARTer can infer optimal DTRs with backward induction algorithms such as Q-learning , which uses the randomized samples for each stage including the enrichment participants. This paper is structured as follows. In Section 2, we introduce SMARTer design and justify the validity under a causal inference framework. In Section 3, we provide the estimation and inference for estimating the mean outcome of a DTR and comparison of two DTRs. In Section 4, we study the efficiency of SMARTer as compared to SMART and compare their sample sizes. Extensive simulation study results are shown in Section 5 to examine the performance of SMARTer, the accuracy of the derived sample size formula, and the robustness of this design. In section 6, we illustrate the sample size calculation under design parameters informed by a real world SMART study of autism disorder. Section 7 provides some preliminary work of finding the optimal DTR based on a SMARTer design and concludes with some discussions.
SMARTer Design

Rationales of the SMARTer Design
The essential idea of a SMARTer design is that at the kth stage (k > 1), enrich the original SMART with new patients randomized among the kth stage treatment options. As illustrated in the flowchart One key eligibility criterion for the enrichment group is that they have received one of the first stage treatments. However, their first stage treatments can be assigned in a naturalist fashion without randomization prior to the enrollment. For the enrichment subjects in group 3, their second-stage treatments will be randomized as in the original SMART.
Taking the autism study (Kasari et al., 2014) as an example, the primary outcome for this study was the total number of spontaneous communicative utterances (TSCU). The response status to the first stage treatment was the intermediate outcome that the second stage treatment choice and randomization probability depended on. For example, for a DTR starting with JASP+EMT, whether a patient participates in the second randomization to add SGD or intensify depends on whether he/she is a slow responder or not. Group 1 patients would be those who were randomized in the first stage and stayed through the trial until the end of the second stage. Group 2 patients include the 6 patients who dropped out after randomization in the first stage, and the additional 3 patients who dropped out after finishing first stage and on whom the intermediate response variables were recorded. In the next few sections, we will provide analysis of efficiency and sample size computation for the enrichment group 3 patients in the new SMARTer design to estimate the mean outcome of a given DTR and compare DTRs.
The final analysis sample of SMARTer consists of three groups of patients (also shown in Figure 1 ). Specifically, group 1 is the n 1 SMART subjects who stay through two stages of randomization and treatments; group 2 is the n 2 SMART subjects who drop out before the second randomization; and group 3 is the m enrichment subjects who only receive the second-stage randomization with known first-stage treatment history. Let Z i denote the indicator of stage 2 completion status for subject i, S i denote pre-treatment information at stage 1, A ki denote treatment at stage k (k = 1, 2), and Y i denote the observed reward outcome from the study. Then SMARTer data consist of the data from the original SMART subjects,
, and the data from the m enrichment subjects,
In the subsequent presentation, we assume S i to take a finite number of discrete values for convenience.
[ 
. Here Y (a 1 , a 2 ) is the potential outcome associated with the treatment assignment (a 1 , a 2 ). We assume the following conditions hold: 
The essential idea is that sequential ignorability assumption required to draw causal inference is satisfied in the enrichment sample when used to predict mean outcomes and compare second stage treatment options. In other words, due to sequential ignorability, potential outcomes {Y (a 1 , a 2 )} are conditionally independent of A 2 given (A 1 , S) in the enrichment sample, even if their first stage treatments can be received in a naturalistic fashion without randomization. When comparing first stage treatment options, we only use the non-dropouts from the original SMART and predicted outcomes for n 2 dropouts whose first stage treatments are randomized. Specifically, let p k (a k |s k ) denote the randomization probability of A k given a patient's covariates collected up to stage k, i.e., s k . Note that for simplicity, here we assume second stage randomization probabilities depend on baseline covariates and first stage treatments.
In Section 2.3, we generalize to allow them to depend on intermediate outcomes. Our key result is to show
denotes the expectation for subjects in group g, and Y * denotes the conditional mean of Y given (A 1 , S, A 2 = d 2 (A 1 , S)) for subjects in group 1 and 3. The rationale is that if this equality holds, then the average causal outcome, Y , but their outcomes can be estimated as Y * from subjects in group 1 and 3; (3) Group 3 subjects contribute to the estimation through estimating missing outcomes for subjects in group 2.
To see why the above equalities hold, first note that under condition (C.1), we obtain
under the non-informative dropout condition (C.2), the above expression becomes
Furthermore, by randomization of A 1 in the first stage for group 1 subjects, we obtain the above equation to also equal the average causal outcome, i.e.,
Next, due to randomization of A 2 for subjects in group 1 and group 3, under condition (C.3), we obtain
Consequently,
Again, by the randomization of A 1 for subjects in group 2, we conclude
Value Estimation and Inference in SMARTer
Given a DTR (d 1 , d 2 ), for a patient with S = s and treatment assignment a 1 = d 1 (s) and
, an estimator of the expected outcome value associated with this DTR is
where Y (a 1 , a 2 , s) is the predicted outcomes for group 2 subjects using group 1 and group 3 data:
The essential idea is to compute the average outcome for subjects in SMART using observed outcomes for group 1 and imputed outcomes for group 2 (imputed using group 1 and 3 data).
The enrichment sample improves estimation efficiency through nonparametric imputation (simple average) for subjects in group 2. Note that from (1), even without an enrichment sample (i.e., m = 0), we can still impute group 2 subjects' outcomes using group 1 subjects' to improve efficiency with no bias. Thus the estimator in (1) deals with missing data issue for SMART design as well. It is clear that the estimator in (1) adheres to the intentionto-treatment principal (Fisher et al., 1989) such that all subjects randomized are analyzed according to their original treatment assignments.
Next, we derive the asymptotic variance formula for estimator (1) under the conditions (C.1) through (C.4) assuming m = O(n). Specifically, we wish to obtain the asymptotic
To this end, we let p(s) be the probability of S = s and p(a 1 |s) be the randomization probability of A 1 = a 1 given S = s in the SMART population in the first stage and let p(a 2 |s, a 1 ) be the randomization probability of A 2 = a 2 given S = s and A 1 = a 1 in the second stage. These two conditional probabilities are known by design. Furthermore, we let q(s) and q(a 1 |s) be the probability of enrichment sample with S = s and receiving first-stage treatment A = a 1 given S = s. Note that due to the observational nature of the enrichment group for the first-stage treatment, q(s) may not equal p(s) and q(a 1 |s) may not equal p(a 1 |s). We let π 1 (a 1 , a 2 , s) = p(a 2 |s, a 1 )p(a 1 |s)p(s),
We show in Appendix B the asymptotic variance of
The first term is the variability from subjects in group 1 and imputing outcomes for group 2, and the second term is the variability from enrichment subjects in group 3. The variance can be estimated by its empirical form.
Finally, to compare two DTRs, we can use the difference of SMARTer estimators for
This variance can also be estimated by its empirical form.
Incorporating intermediate outcomes
The previous section assumes no intermediate outcome is available especially for subjects who drop out from the SMART. When intermediate outcomes on these subjects are available, con-
, where the treatment rule d 2 may depend on the intermediate outcome.
In this case, the observed data from a SMARTer consist of ( For simplicity of derivation, we assume S 1i and S 2j to be discrete. Similar to (1), a consistent estimator of the associated value using both the SMART and enrichment observations is
where Y (a 1 , a 2 , s) is the imputed outcome from the second-stage data given as
The asymptotic variance is similar to before by re-defining π k (a 1 , a 2 , s) as π k (a 1 , a 2 , s 1 , s 2 ) through conditioning on both the baseline covariates S 1 and intermediate outcome S 2 . That is,
Design Efficiency of SMARTer
In this section, we study the efficiency gain or loss of the proposed design as compared to a SMART with no dropout. For simplicity of illustration, we assume P (Z = 1|A 1 , S)
to be a constant, i.e., α(a 1 , s) = α, and let ω(s) = r(d 1 (s), s). Furthermore, we denote
where E s [·] is the expectation with respect to S in the SMART population,
When α = 1, i.e., no participant drops out from SMART, V reduces to
which is the variance formula given in Murphy (2005) for SMART. Therefore, to measure the efficiency gain of the proposed design over SMART design without dropouts, we define relative efficiency ρ = V 0 /V , where ρ > 1 implies the propose enrichment design is more efficient than the original SMART without dropout.
To further gain insights on efficiency comparison, we consider a special situation when treatment randomization does not depend on tailoring variables, i.e., p 1 (S) = p 1 , p 2 (S) = p 2 .
We also assume that the enrichment population is close to the original SMART population so ω(s) ≈ 1, and let the ratio of within-and between-strata variance to be γ ≈ σ(s)
Let α denote the completion (non-dropout) rate, and β = m/n denote the enrichment rate. We can show that
From (2), the relative efficiency depends on randomization probabilities, within-and betweenstrata (S) variability and distribution ratios between the enrichment and SMART populations. Note that ρ > 1 implies the proposed SMARTer is more efficient than a SMART without enrichment and no dropout. From the expression of ρ, we thus conclude:
(1) When α = 1, there is no dropout after the first stage in SMARTer, our estimator reduces to be the same as the estimator in Murphy (2005) , and thus ρ = 1.
(2) When α = 0, that is, all subjects drop out after the first stage, ρ ≈ (1 + γ)/(p 2 + γ/β).
There is efficiency gain if β > γ/(1 + γ − p 2 ). More specifically, there is always efficiency gain if β > 1. Note that this is the extreme case in the sense that all subjects drop out and we synthesize two independent randomized trials on the two stages.
(3) For any 0
Particularly, the latter condition holds if we choose β 1. corresponds to β = 0.5. That is, at 60% completion rate, a study needs to enrich 50%
sample to obtain a SMARTer estimator with variance 1/0.9 ≈ 1.11 times the variance of SMART estimator with the same initial sample size but no dropout. Similarly, at the same completion rate, to achieve the same efficiency, β needs to be above 0.75; and to achieve a relative efficiency of ρ = 1.1, β need to be above 1.05. Note that the line with equal efficiency has a slow change rate indicating the increase of enrichment sample size is not sensitive to completion rate. The contour lines above the equal efficiency line (ρ = 1) are convex and increasing, indicating with lower dropout rate after the first stage, SMARTer requires more enrichment patients at the second stage to achieve higher efficiency than a SMART with no dropout. The opposite can be seen from the contour lines below the equal efficiency line which are concave and decreasing: with lower dropout rate, SMARTer requires less enrichment patients or no enrichment to achieve efficiency slightly lower than a SMART with no dropout.
[ Figure 2 about here.]
Another way to understand the design efficiency of SMARTer is through sample size calculation for comparing two DTRs in a SMARTer study. We denote the difference in the mean outcome value as ∆µ and assume the type I error rate of a two-sided test is 0.05 and 80% power to detect a difference. In the above simplified setting, the total sample size of 
, then ρ is also the ratio of variance of SMART and SMARTer estimator for comparing two DTRs. Thus the sample size of initial recruitment (n) for a SMARTer is 8(z 0.05/2 + z β ) 2 σ 2 (∆µ) 2 ρ to achieve the same efficiency. Table 1 provides the sample sizes for a SMARTer with an initial sample of n subjects and an enrichment sample of m subjects to achieve the same efficiency as a SMART recruiting 100 subjects and in an ideal case of no dropout. For example, if 40% patients drop out after the first stage randomization of SMARTer and the within-and between-stratum variance ratio γ = 1, Table 1 provides three combinations of initial stage and enrichment sample sizes for SMARTer to achieve the same efficiency: (109, 54), (80, 80) and (62, 124) . In contrast, when accounting for dropouts at the design stage for a SMART without enrichment, one needs 100/0.6=250 subjects.
Simulation Studies
Simulations results are based on 1000 replications of samples with initial enrollment of n = 800 patients. They demonstrate the consistency and comparative efficiency of SMARTer compared with SMART under various scenarios with or without intermediate outcomes.
Simulation Results without Intermediate Outcomes
Here we assume there are two stages each with 2 candidate treatments, A 1 and A 2 , and a randomization probability of 1/2. The baseline covariate S 1 takes random integer values (0, 1, 2) with probabilities (1/3, 1/3, 1/3). Let S 2 = A 1 (1 − S 1 ), and the final outcome after the second stage is Y = S 2 + A 2 (1 − S 1 ) + I(S 1 = 1, A 1 = 1, A 2 = −1) + e, where e ∼ N (0, 1).
The optimal dynamic rules for this setting are d 1 (S 1 ) = 2I(S 1 < 2) − 1 and d 2 (S 1 , A 1 ) = 2I(S 1 < 1) − 1. Under this rule ν(S 1 = 0) = 2, ν(S 1 = 1) = 1, ν(S 1 = 2) = 2, thus the optimal rule has a value of µ(d 1 , d 2 ) = 1.667. We consider two levels of completion rates α = 0, 0.5, three levels of enrichment proportions β = 0.5, 1, 2 and two scenarios for the m enrichment patients with the baseline distribution of q = (1/2, 1/4, 1/4) for S 1 : scenario 1 simulates the distribution of A 1 for the enrichment patients the same as initially recruited patients, i.e., q(A 1 |S 1 ) = p(A 1 |S 1 ) = 1/2; and scenario 2 simulates different observed A 1 distribution q(A 1 = 1|S 1 ) = 1/(1 + exp(−0.5(2I(S 1 < 2) − 1))), that is, the enrichment patients are more likely to receive the optimal first-stage treatment. Table 3 presents SMARTer estimators of a single DTR and comparison of two DTRs, as well as their efficiency gain (ρ) compared with SMART without dropout. We provide the estimates for the optimal treatment regime d 1 (S 1 ) = 2I(S 1 < 2) − 1 and d 2 (S 1 , A 1 ) = 2I(S 1 < 1) − 1, and its comparison with an one-size-fits-all regime, d 1 (S 1 , A 1 ) = −1 and d 2 (S 1 , A 1 ) = 1, for which the mean outcome is µ = 0.
The results show the accuracy of the variance estimation and the simplified formula (2) of comparative efficiency. When all patients drop out (α = 0), the relative efficiency ρ increases from about 0.5 to 2 when the enrichment size m increases from 0.5 to 2 times the original sample size n; when half of patients drop out (α = 0.5), the relative efficiency ρ increases from about 0.9 to 1.3. As β increases, SMARTer is more efficient comparing to SMART design even when all patients drops out after the initial randomization (α = 0) and SMARTer combines two single-stage randomized trials. We also observe that the relative efficiency ρ for comparing two DTRs is greater (more efficient) than estimating a single DTR.
Simulation Results with Intermediate Outcomes
The general settings are the same with section 5.1. The intermediate outcome before the second stage treatment S 2 is simulated from a logistic model, where logit{P (S 2 = 1|A 1 , S 1 )} = A 1 (1 − S 1 ), and the outcome after the second stage treatment is Y = S 2 + A 2 (1 − X) + I(X = 1)A 2 (2S 2 − 1) + e, where e ∼ N (0, 1). The dynamic rules we are considering is the optimal rule under this scenario, which also depends on the intermediate outcome S 2 :
Under this rule ν(S 1 = 0) = 1 + e 1+e , ν(S 1 = 1) = 1.5, ν(S 1 = 2) = 1 + e 1+e
. Thus the mean outcome for the optimal rule is µ (d 1 , d 2 ) = 1.654 with equal baseline distribution for S 1 . Table 3 presents SMARTer estimators of both a single DTR and comparison of two DTRs, as well as their efficiency gain (ρ) compared with SMART estimator with no dropout. We present the estimates for the optimal DTR and its comparison with an one-size-fits-all rule: d 1 (S 1 , A 1 ) = −1 and d 2 (S 1 , A 1 , S 2 ) = 1, for which the mean outcome is µ = 0.5. The true mean difference is 1.154. The results are similar to the case without intermediate outcome.
When β = 1,ρ is approximately equal or larger than 1, and it is higher for the difference comparison in Table 4 . We observe that SMARTer estimator has efficiency gain even with β = 1 and it may boost efficiency especially when comparing two DTRs.
Sample size calculation for an Autism SMART study
We illustrate the sample size calculation and potential efficiency gain using results from the autism study (Kasari et al., 2014) introduced in Section 2.1. For the primary aim, they study found that SGD(JASP+EMT+SGD) has a better treatment effect compared with spoken words alone (JASP+EMT). Secondary aim results suggest that the adaptive intervention beginning with JASP+EMT+SGD and intensifying JASP+EMT+SGD for children who were slow responders led to better post-treatment outcomes.
Suppose we stratify by baseline variables and responding status (early or slow) after the first stage. Here we provide the sample size calculation for comparing two adaptive treatment regimes as in the secondary study aim: one is starting with JASP+EMT+SGD and intensifying JASP+EMT+SGD for children who are slow responders (d 2 ); the other is starting with JASP+EMT, and the slow-responders to JASP+EMT receive JASP+EMT+SGD (d 2 ).
The original planned sample size was based on the primary aim to compare TSCU for two treatments in stage 1. The study assumed an attrition rate of 10% by week 24, and the planned total sample size was n = 97 to detect a moderate effect size of 0.6 in TSCU with 80% power using a two-sided two-sample t-test with a type I error rate of 5%. The actual study recruited 61 patients. The effect size for the primary aim comparison was 0.62 and it was significant at 0.05 level despite the insufficient power. As a secondary aim of the study, the effect size of the embedded DTRsd 2 andd 2 for TSCU at week 24 was 0.55. There were approximately 15% patients dropped out after the first stage at week 12. The comparison of two DTRs in the secondary aim had approximately a power of 37% to detect a moderate effect size of 0.5.
We examine whether one can design a SMARTer to enrich the trial in the second stage so that the power for comparing two DTRs can be improved. To this end, note the following
, where ∆µ is the effect size, and
When γ = 0.5, we have Z β −0.115 and we can achieve at most 55% in power by enrichment in the second stage. To achieve 80% power, one needs to at least recruit 151 patients in the first stage. .
Since we do not have information on the ratio of within and between stratum variances γ, we provide results for three ratios γ = 0.2, 0.5, 1 and also two rates of attrition 15% and 40% after the first stage. According to Table 2 , for this specific example, SMARTer would have smaller total sample size for initial recruitment and enrichment when γ is small (γ = 0.2) with attrition rate 15% and for γ = 0.5 with attrition rate 40%. SMARTer would be more beneficial for smaller sample sizes and when both groups being compared receive two stages of randomization.
Discussion
We propose a SMARTer design to improve efficiency over SMART by enriching study participants at each stage of a multi-stage trial. We have shown that the new design retains the validity of making causal inference for DTRs and the efficiency gain is significant if drop out rate is considerable and the enrichment sample size is substantial. In all numeral results, we compared efficiency of SMARTer to SMART with no dropout. When comparing with SMART accounting for dropouts, the efficiency gain is expected to be greater than that shown here. One interesting application of SMARTer design is the extreme case when α = 0, so the proposed design is equivalent to synthesizing different independent trials from each stage. One important implication is that if the conditions (C.1)-(C.4) hold, i.e., the treatment response profiles are the same for the participants from each stage and the treatment history in previous stages of the enrichment sample can be obtained, then we no longer need to conduct a full SMART in order to evaluate DTRs. Therefore, in practice, it may be possible to synthesize existing trials conducted at separate stages to compare DTRs, at least for the purpose of discovering optimal DTRs. At the other extreme, when there is no attrition (i.e., α = 1) SMARTer can still be used to gain efficiency by replacing Y i in µ (d 1 , d 2 ) by the corresponding stratum mean estimated from the combined SMART and enrichment sample, which is less variable.
Data collected from the SMARTer can also be used to find optimal DTR using methods such as Q-learning Watkins, 1989) . Using a two-stage design as an example, first one can find the optimal second stage treatment using the subjects randomized at the second stage, which includes n 1 group 1 subjects and the m group 3 enrichment subjects. Next, one can use the regression model in Q-learning from this step to predict the optimal outcomes of the group 2 dropout subjects and identify optimal second stage treatment. Lastly, group 1 and 2 subjects are used to estimate the optimal treatment rule for the first stage. More details on how to estimate the optimal rule and a simulation study are included in the Web Appendix B.
Unmeasured confounding may be a concern in statistical inference using enrichment group observational data. However, note that the enrichment sample is only used to predict out- From the real data example in Section 6, we see that although enrichment can improve the power for comparing DTRs, the maximal power one can attain still depends on the sample size in the first stage recruitment. Recruiting an enrichment sample can decrease the within-stratum variation but can not decrease the variation from between-stratum variation.
Therefore, in reality practitioners may design a SMART with a sample size assuming a small drop out after the first stage, and consider enriching the study sample at the second stage to achieve the predetermined power if the actual observed dropout rate is high during the first stage of treatment. In this case, SMARTer may act as a salvage design to mitigate high drop out rate. In addition, one major reason for the low participation rate in clinical trials and high attrition is the need for frequent in-person visits and the resulting time and travel costs (Ross et al., 1999) , which can be reduced for the enrichment samples in SMARTer since these participants have already received first stage treatments. For the enrichment sample, the cost of monitoring first stage treatment is saved, and the duration of trial for this group can be considerably less than recruiting patients in the first stage to under go multiple randomizations. The chance to retain participants in the trial can be much higher.
Finally, from a design point of view, although we allow the distribution of first-stage treatment history and covariates on the enrichment participants to be different from the SMART population, the more similar they are, the more efficiency we will gain by using the enrichment participants. This implies that when recruiting enrichment patients for the second stage treatments, similar inclusion/exclusion criteria as SMART may be used and certain sampling design may be implemented to improve matching. Furthermore, since SMARTer requires the treatment responses between the enrichment and SMART population to have the same distributions, caution should be taken when one suspects that the two populations may have different response mechanisms to treatments. Sensitivity analysis can be conducted in the analysis phase.
Web Appendix
In the web appendix, we provide derivation of the asymptotic variance of the estimator for expected outcome under a given DTR, as well as description and preliminary simulation results for learning the optimal DTR from SMARTer.
[ Table 1 Sample sizes for SMARTer are to achieve same power as a SMART trial with the same initial recruitment as n and in an ideal case of no dropout. n is the sample size for the SMART group, m is the sample size for the enrichment group; γ is ratio of within-and between-stratum variance. Note: α represents probability of non-dropout; β = m/n; ρ is the relative efficiency using the formula in Section 4, and ρ is the empirical efficiency; scenario 1: the enrichment population has distritubiton q = (1/2, 1/4, 1/4) for (0, 1, 2), and q(A1|S1) = 1/2; scenario 2: q = (1/2, 1/4, 1/4) and observed treatment A1 distribution q(A1 = 1|S1) = 1/(1 + exp(−0.5(2I(S1 < 2) − 1))) † : Efficiency ρ is the same for estimating one DTR and comparing two DTRs with different first stage treatments 
